SequelSEC

PROCYON CORP PCYN

Pharmaceutical Preparations · CIK 0000812306 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$4.98M
Fiscal year ended 2024-06-30
Operating income
-$231.70K
Fiscal year ended 2024-06-30
Free cash flow
-$125.16K
Fiscal year ended 2024-06-30

Valuation, from the filing

Public float$1.02MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-09-24
Float per share$0.13Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-09-24, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue0.6%2th
Operating margin-4.6%76th
Net margin-6.8%71th
FCF margin-2.5%69th
Gross margin78.1%65th
Current ratio3.08x42th
CapEx / revenue1.3%43th
Revenue YoY growth6.4%53th

PROCYON CORP (PCYN) reported revenue of $4.98M and net income of -$341.14K for the fiscal year ended 2024-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from PROCYON CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PROCYON CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-06-30
Revenue$4.98M
Cost of revenue$1.09M
Gross profit$3.89M
Operating income-$231.70K
Net income-$341.14K
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$171.28K
Income tax expense$169.86K
Diluted EPSUnavailable
Selling, general & administrative$2.04M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

PROCYON CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-06-30
Cash & equivalentsUnavailable
Total assets$3.20M
Current assets$2.37M
Total liabilities$917.12K
Current liabilities$769.23K
Total equity incl. NCI$2.29M
Temporary (mezzanine) equityUnavailable
Inventory$510.01K
Accounts receivable$512.91K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$160.92K

Cash flow

PROCYON CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-06-30
Operating cash flow-$61.25K
Capital expenditures$63.91K
Investing cash flow-$63.91K
Financing cash flowUnavailable
Net change in cash-$125.16K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

PROCYON CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-06-30
Free cash flow-$125.16K
Gross margin78.1%
Operating margin-4.6%
FCF margin-2.5%
SBC / revenueUnavailable
Current ratio3.08x
Revenue YoY growth6.4%
Net margin-6.8%
R&D / revenueUnavailable
CapEx / revenue1.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PCYN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2024-10-25View SEC filing
10-Q · Filed 2024-05-24View SEC filing
10-Q · Filed 2024-02-22View SEC filing
10-Q · Filed 2023-11-22View SEC filing
10-K · Filed 2023-09-28View SEC filing
10-Q · Filed 2023-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.